NEUROPHTH THERAPEUTICS
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
NEUROPHTH THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science
Founded:
2016-07-01
Address:
Wuhan, Hubei, China
Country:
China
Website Url:
http://www.neurophth.com
Total Employee:
251+
Status:
Active
Contact:
+027-65524119
Total Funding:
140.3 M USD
Technology used in webpage:
DNS.COM
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
Sunshine Insurance Group
Sunshine Insurance Group investment in Series C - Neurophth Therapeutics
CMB International Capital Corporation
CMB International Capital Corporation investment in Series C - Neurophth Therapeutics
Sequoia Capital China
Sequoia Capital China investment in Series C - Neurophth Therapeutics
CMG-SDIC Capital Management
CMG-SDIC Capital Management investment in Series C - Neurophth Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Neurophth Therapeutics
InnoVision Capital
InnoVision Capital investment in Series B - Neurophth Therapeutics
Harvest Capital
Harvest Capital investment in Series B - Neurophth Therapeutics
Guofang Capital
Guofang Capital investment in Series B - Neurophth Therapeutics
Sequoia Capital China
Sequoia Capital China investment in Series B - Neurophth Therapeutics
Grand Mount Capital
Grand Mount Capital investment in Series B - Neurophth Therapeutics
Key Employee Changes
Official Site Inspections
http://www.neurophth.com
- Host name: 118.31.117.200
- IP address: 118.31.117.200
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Neurophth Therapeutics"
neurophth
纽福斯生物,纽福斯,眼科基因治疗,neurophthSee details»
COMPANY PROFILE - neurophth
Neurophth is China's leading in-vivo gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for …See details»
Neurophth biological tech
Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON. Prof. Bin Li (the founder of Neurophth) initiated gene therapy …See details»
Neurophth Therapeutics - Crunchbase Company Profile & Funding
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients …See details»
Neurophth’s trial for LHON therapy reaches enrolment milestone
Feb 20, 2024 · Neurophth Therapeutics has successfully completed patient enrolment in the Phase I/II trial of Opvika for Leber hereditary optic neuropathy.See details»
Neurophth Company Profile 2024: Valuation, Funding & Investors
Developer of gene therapies designed to treat ophthalmological disorders.See details»
Neurophth Biotechnology - Overview, News & Similar companies
Jun 1, 2023 · Neurophth Biotechnology contact info: Phone number: +86 2765524119 Website: www.neurophth.com What does Neurophth Biotechnology do? Founded in 2016 and based …See details»
Neurophth Therapeutics - VentureRadar
Neurophth Therapeutics Ltd., (“Neurophth”) is a fully integrated genomic medicines company aiming to improve lives through the curative potential of gene therapies. Neurophth’s lead …See details»
Neurophth Therapeutics - Contacts, Employees, Board Members, …
Neurophth Therapeutics has 8 current employee profiles, including Chief Operating Officer & Chief Medical Officer Zhang Xin. Neurophth is China's first gene therapy company for …See details»
Neurophth Raised Over $60 Million USD in Series-C Financing to …
Nov 23, 2021 · Neurophth is China's first gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San Diego, California), …See details»
Neurophth Secures $95 Million for Gene Therapy Clinical Trials
Aug 11, 2023 · Neurophth Therapeutics, a Chinese gene therapy company focused on genetic ophthalmic diseases, raised nearly $95 million in a series C+ financing to advance clinical …See details»
Neurophth opens GMP manufacturing facility for gene therapy …
Sep 28, 2021 · Neurophth Biotechnology Ltd. has opened a manufacturing facility at the Phase II Suzhou Biomedical Industrial Park (BioBAY) in Suzhou, China. Neurophth is China’s first gene …See details»
Cyagen and Neurophth Enter Global Strategic Collaboration to …
Nov 8, 2022 · Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc.to co-develop next-generation AAV gene therapy vectors for specific types of genetic …See details»
Neurophth Announces Completion of Patient Enrollment for …
Feb 19, 2024 · Neurophth is China's leading in-vivo gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San Diego, …See details»
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic ...
Jan 25, 2022 · Neurophth is China's first gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San Diego, California), …See details»
Optic Atrophy Gene Therapy Cleared for Trials in Australia
Sep 25, 2023 · NFS-05 is an ophthalmic injection that uses an AAV vector to deliver the OPA1 gene to retinal ganglion cells. Neurophth’s NFS-05 gene therapy has been cleared by the …See details»
Neurophth announces first patient dosed in Phase III clinical trial …
Sep 27, 2022 · Neurophth is conducting a Phase I/II/III, multi-center, two-parts study aimed at evaluating the safety, tolerability, and efficacy of NR082 in LHON patients with ND4 mutations. …See details»
Neurophth Closes RMB 400 Million Series B Financing - PR Newswire
Feb 9, 2021 · WUHAN, China and NEWARK, Del., Feb. 9, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered …See details»
Neurophth Therapeutics’ ND1-LHON Gene Therapy Trial
Aug 24, 2023 · NFS-02 is currently the only ND1-LHON treatment in development worldwide. In response to patients’ expectations, we are committed to conduct global multiregion, …See details»
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical ...
Jan 19, 2022 · With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San Diego, California), Neurophth, a fully-integrated company, is striving to discover and develop genomic …See details»